Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mari

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Thrombosis Research|February 1, 1996
Hypercoagulability and hyperfibrinolysis in patients with melanomaB Bottasso, D Mari, R Coppola, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 1, 1996
Measurement of activated factor XII in health and diseaseR Coppola, P Cristilli, M Cugno, et al.
Blood|June 1, 1995
Hypercoagulability in centenarians: the paradox of successful agingD Mari, P M Mannucci, R Coppola, et al.
Haematologica|September 1, 1991
Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia. Case reportsE Bottini, F I Pareti, D Mari, et al.
La Ricerca in Clinica E in Laboratorio|January 1, 1985
[The role of erythrocyte deformability in the prolonged bleeding time in liver disease patients]M Moia, D Mari, M P Coccato, et al.
Thrombosis and Haemostasis|February 1, 1996
Hemostasis abnormalities in patients with vascular dementia and Alzheimer's diseaseD Mari, L Parnetti, R Coppola, et al.
Cancer|December 24, 1997
A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responsesD Tummarello, D Mari, F Graziano, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 16, 2004
Metabolic gene polymorphisms and p53 mutations in healthy centenarians and younger controlsL Gaspari, P Pedotti, M Bonafè, et al.
Anticancer Research|September 1, 1994
Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapyD Tummarello, F Graziano, D Mari, et al.
Bulletin Du Cancer. Radiotherapie : Journal De La Societe Francaise Du Cancer : Organe De La Societe Francaise De Radiotherapie Oncologique|January 1, 1996
Changes in biological effectiveness with depth of the Medicyc neutron therapy beamA Courdi, N Brassart, J Hérault, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Thrombosis Research|February 1, 1996
Hypercoagulability and hyperfibrinolysis in patients with melanomaB Bottasso, D Mari, R Coppola, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 1, 1996
Measurement of activated factor XII in health and diseaseR Coppola, P Cristilli, M Cugno, et al.
Blood|June 1, 1995
Hypercoagulability in centenarians: the paradox of successful agingD Mari, P M Mannucci, R Coppola, et al.
Haematologica|September 1, 1991
Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia. Case reportsE Bottini, F I Pareti, D Mari, et al.
La Ricerca in Clinica E in Laboratorio|January 1, 1985
[The role of erythrocyte deformability in the prolonged bleeding time in liver disease patients]M Moia, D Mari, M P Coccato, et al.
Thrombosis and Haemostasis|February 1, 1996
Hemostasis abnormalities in patients with vascular dementia and Alzheimer's diseaseD Mari, L Parnetti, R Coppola, et al.
Cancer|December 24, 1997
A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responsesD Tummarello, D Mari, F Graziano, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 16, 2004
Metabolic gene polymorphisms and p53 mutations in healthy centenarians and younger controlsL Gaspari, P Pedotti, M Bonafè, et al.
Anticancer Research|September 1, 1994
Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapyD Tummarello, F Graziano, D Mari, et al.
Bulletin Du Cancer. Radiotherapie : Journal De La Societe Francaise Du Cancer : Organe De La Societe Francaise De Radiotherapie Oncologique|January 1, 1996
Changes in biological effectiveness with depth of the Medicyc neutron therapy beamA Courdi, N Brassart, J Hérault, et al.
Pageof 7